Development
Gilead Sciences, Inc.
GILD
$112.46
-$2.05-1.79%
NASDAQ
| 12/31/2023 | 09/30/2023 | ||||
|---|---|---|---|---|---|
| Revenue | 0.91% | 6.83% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 0.91% | 6.83% | |||
| Cost of Revenue | 0.00% | 8.53% | |||
| Gross Profit | 1.17% | 6.36% | |||
| SG&A Expenses | 22.28% | -28.88% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 5.61% | -7.57% | |||
| Operating Income | -6.59% | 42.22% | |||
| Income Before Tax | -28.65% | 45.97% | |||
| Income Tax Expenses | 62.33% | -73.41% | |||
| Earnings from Continuing Operations | -34.76% | 109.05% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | 50.00% | 33.33% | |||
| Net Income | -34.45% | 108.61% | |||
| EBIT | -6.59% | 42.22% | |||
| EBITDA | -5.15% | 31.24% | |||
| EPS Basic | -34.45% | 108.77% | |||
| Normalized Basic EPS | -7.05% | 46.34% | |||
| EPS Diluted | -34.73% | 108.43% | |||
| Normalized Diluted EPS | -6.98% | 46.33% | |||
| Average Basic Shares Outstanding | 0.00% | -0.08% | |||
| Average Diluted Shares Outstanding | -0.08% | -0.08% | |||
| Dividend Per Share | 0.00% | 0.00% | |||
| Payout Ratio | 0.51% | -0.52% | |||